Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Andre De Souza; Fabio A Tavora; Devalingam Mahalingam; Pamela N Munster; Howard P Safran; Wafik S El-Deiry; Benedito A Carneiro

doi:10.3389/fimmu.2020.595289

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Front Immunol. 2020 Oct 19:11:595289. doi: 10.3389/fimmu.2020.595289. eCollection 2020.

Authors

Andre De Souza¹, Fabio A Tavora², Devalingam Mahalingam³, Pamela N Munster⁴, Howard P Safran¹, Wafik S El-Deiry^{1

5}, Benedito A Carneiro¹

Affiliations

¹ Division of Hematology/Oncology, Lifespan Cancer Institute, Warren Alpert Medical School of Brown University, Providence, RI, United States.
² Argos Laboratory, Fortaleza, Brazil.
³ Division of Hematology/Oncology, Northwestern University, Chicago, IL, United States.
⁴ Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States.
⁵ Department of Pathology and Laboratory Medicine, Alpert Medical School of Brown University, Providence, RI, United States.

No abstract available

Keywords: 9-ING-41; COVID; COVID-19; GSK-3 inhibitor; GSK-3b inhibitor; SARS-CoV21; glycogen synthase kinase-3 (GSK-3) inhibitor; glycogen synthase kinase-3 (GSK3).

Publication types

Comment

MeSH terms

Glycogen Synthase Kinase 3*
Immune System Phenomena*
Protein Kinase Inhibitors
Virus Replication

Substances

Protein Kinase Inhibitors
Glycogen Synthase Kinase 3